Active, not recruitingPhase 2NCT04802590
Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma
Studying Mantle cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- The Lymphoma Academic Research Organisation
- Principal Investigator
- Steven Le GouillLymphoma Study Association
- Intervention
- Ibrutinib 560 mg(drug)
- Enrollment
- 194 target
- Eligibility
- 18-79 years · All sexes
- Timeline
- 2022 – 2031
Study locations (30)
- A.Z. Sint Jan AV, Bruges, Belgium
- Universite Libre de Bruxelles - Hopital ERASME, Brussels, Belgium
- Hopital Jolimont, Haine-Saint-Paul, Belgium
- CHU de Liege, Liège, Belgium
- Universite Catholique de Louvain Mont Godinne, Yvoir, Belgium
- CHU d'Angers, Angers, France
- CH d'Avignon - Hopital Henri Duffaut, Avignon, France
- CH de la Côte Basque, Bayonne, France
- CHU Jean Minioz, Besançon, France
- Chu de Brest - Hopital de La Cavale Blanche, Brest, France
- Institut d'Hématologie de Basse Normandie, Caen, France
- Chu Estaing, Clermont-Ferrand, France
- CH Henri Mondor, Créteil, France
- CHU de DIJON, Dijon, France
- CHD de Vendée, La Roche-sur-Yon, France
- +15 more locations on ClinicalTrials.gov
Collaborators
Institute of Cancer Research, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04802590 on ClinicalTrials.govOther trials for Mantle cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07377578A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell LymphomaGuangzhou Lupeng Pharmaceutical Company LTD.
- RECRUITINGPHASE2NCT07272499Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk DiseaseRuijin Hospital
- RECRUITINGPHASE2NCT07029737A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in SpainAstraZeneca
- RECRUITINGNANCT07257510Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell LymphomaPeking University Third Hospital
- RECRUITINGPHASE2NCT06846489Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell LymphomaSun Yat-sen University
- RECRUITINGPHASE3NCT06742996A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)BeOne Medicines
- RECRUITINGNCT06788652A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing SettingJuno Therapeutics, Inc., a Bristol-Myers Squibb Company
- RECRUITINGPHASE2NCT06522386GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell LymphomaM.D. Anderson Cancer Center